Polymorphisms of the ICAM-1 exon 6 (E469K) are associated with differentiation of colorectal cancer by Wang, Qing-lei et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Journal of Experimental & Clinical 
Cancer Research
Open Access Research
Polymorphisms of the ICAM-1 exon 6 (E469K) are associated with 
differentiation of colorectal cancer
Qing-lei Wang1, Bing-hui Li*2, Bin Liu1, Ya-bin Liu2, Yue-Ping Liu2, Sui-
Bing Miao1, Yi Han1, Jin-Kun Wen1 and Mei Han1
Address: 1Department of Biochemistry and Molecular Biology, Institute of Basic Medicine, Hebei Medical University, No 361, Zhongshan East 
Road, Shijiazhuang, 050017, China and 2Department of Surgery, Fourth Hospital, Hebei Medical University, Shijiazhuang, 050011, China
Email: Qing-lei Wang - walksweet@foxmail.com; Bing-hui Li* - lbh58@hebmu.edu.cn; Bin Liu - liubin-good@sohu.com; 
Ya-bin Liu - hanmei@hebmu.edu.cn; Yue-Ping Liu - hanmei@hebmu.edu.cn; Sui-Bing Miao - msbgy@126.com; Yi Han - hanyi0311@163.com; 
Jin-Kun Wen - wjk@hebmu.edu.cn; Mei Han - hanmei@hebmu.edu.cn
* Corresponding author    
Abstract
Background:  Genetic factors are thought to play a role in development for colorectal
carcinogenesis. ICAM-1 is a polymorphic gene, thus, the present study investigated the relationship
between the polymorphisms of ICAM-1 and the susceptibility and phenotypical characteristics of
colorectal cancer (CRC).
Methods: The polymorphisms at ICAM-1 exon 4 (G241R) and exon 6 (E469K) were detected by
PCR with sequence-specific primers. The relationship between specific genotypes of ICAM-1 and
differentiation of CRC was evaluated by the histological grade.
Results: We showed only GG genotype of ICAM-1 individuals in either CRC or normal controls.
The KK genotype of ICAM-1 K469E was found more frequently than in the controls (P < 0.05).
Patients with well-differentiated CRC displayed the KK more frequently than those of poor
differentiation (P < 0.05).
Conclusion: The findings indicate that polymorphisms of G241R are rare in Chinese population
and that KK genotype of ICAM-1 K469E is significantly associated with well differentiation of CRC.
Background
Colorectal cancer (CRC) is a common malignant disease
around the world. CRC has an extremely poor prognosis
owing to insidious symptomatology, late clinical presen-
tation and rapid progression and so lead to poor 5-year
disease-free survival [1,2]. CRC is related not only to liv-
ing habits such as dietary but also to the susceptibility of
heredity [3]. Individuals who have first-degree relative
with CRC have the increased risk of the CRC compared
with those without a family history [4], suggesting that
genetic factors contribute to risk for colorectal carcinogen-
esis [5].
The intercellular adhesion molecule-1 (ICAM-1) is a sin-
gle-chain cell surface glycoprotein that belongs to the
immunoglobulin superfamily. It is known that ICAM-1
can be aberrantly expressed in CRC and suppress cancer
progression via activation of the host immune surveil-
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lance system and prevention of cells from detaching from
the primary tumor mass and thus attenuate or eliminate
metastasis [6,7]. Two single-base polymorphisms in
human ICAM-1 gene have been reported, in exon 4 and 6,
changing codons 241(G241R) and 469(K469E), respec-
tively, which are common genetic variations associated
with diseases [8]. However, it is not well documented that
the association of the ICAM-1 gene polymorphisms with
CRC development. In present study, we analyze the asso-
ciation between the polymorphisms at exon 4 (G241R)
and exon 6 (E469K) of ICAM-1 and CRC susceptibility
and in vivo differences in ICAM-1 level and differentia-
tion in tumor tissues of patients with CRC. Our results
suggest that tumor cell differentiation may be influenced
by genetic variation in ICAM-1 in Chinese population.
Materials and methods
Study population
87 cases were patients with a new diagnosis of colorectal
adenocarcinoma attending a Hebei Medical University
Forth Hospital, China between December 2007 and
August 2008. 102 volunteers without CRC were used as
controls. The average age of the subjects was 55 years
(range, 34-83 years). The peripheral blood specimens
from patients with CRC and controls were collected at the
time of the diagnosis after informed consent was
obtained. All the tumor and matched normal tissues
investigated in this study were obtained from patients
who had undergone a surgical resection. The diagnosis
and staging of CRC were assessed according to the WHO
classifications [9] and TMN classifications [10]. The study
was approved by the institutional research board at Hebei
Medical University.
Genotyping of ICAM-1 gene polymorphisms
Genomic DNA was extracted and purified from whole
blood lymphocytes using a blood DNA Kit (Omega Bio-
Tek Co., USA) according to the manufacturer's instruc-
tions. PCR with sequence-specific primers (SSP) was used
to detect the ICAM-1 polymorphisms at Exon 4 (G241R)
and Exon 6 (E469K) as described elsewhere [11,12]. For
G241R in exon 4, two sequence-specific forward primers:
5'-GTGGTCTGTTCCCTGGACG-3'(G241) and 5'-GTGG
TCTGTTCCCTGGACA-3' (R241), and for K469E (exon 6)
two sequence-specific reverse primers: 5'-GCACAT-
TCACGGTCACCTC-3' (K469) and 5'-GCACATTCACG-
GTCACCTT-3' (E469) were used. Each combination of the
four primers contained one forward primer and one
reverse primer for the 927 bp fragment of sequence-spe-
cific amplifications, respectively. For the positive internal
control, the primers 5'-GAAGGTGAAGGTCGGAGT-
3'(forward) and 5'-GAAGATGGTGATGGGATTTC-3'
(reverse) coding for the 225 bp fragment of human glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) gene
were used.
PCR was performed in a final volume of 20 μl in 96-well
plates. The final concentrations of the reagents were as fol-
lows: 200 μM of each dNTP, 2.5 mM MgCl2, 0.5 μM of
each primer, polymerase buffer, between 0.01 and 0.1 mg
DNA, and 0.2 units of Taq polymerase (Promaga). The
PCR cycle conditions were 94°C for 4 min, followed by 35
cycles at 94°C for 30 s, 69°C for 45 s and 72°C for 40 s,
with a final extension step at 72°C for 10 min. 927 bp of
PCR product was identified by gel electrophoresis on 2%
agarose gels stained with ethidium bromide.
ICAM-1 expression analysis
Western blot analysis was used to detect ICAM-1 protein
expression in both tumor and matched adjacent normal
tissues from patient with CRC as described previously
[13]. The tissue lysates were prepared from the colorectal
tissues [14]. Equal amounts of proteins were separated by
electrophoresis on an 8% SDS-polyacrylamide gel and
then electrophorytically transferred to polyvinylidene dif-
luoride membranes (Millipore Co, Billerica, Massachu-
setts, USA). The membrane was incubated with anti-
ICAM-1 antibody (1:1000; Santa Cruz), followed by a sec-
ondary anti-rabbit antibody (1:20000; Santa Cruz) using
chemiluminescence protocol (Santa Cruz).
Immunohistochemistry analysis
Immunostaining of sections from CRC tissues was per-
formed with the anti-ICAM-1 (1:200) as described previ-
ously [15]. Staining intensities were determined by
measuring the integrated optical density (IOD) with light
microscopy using a computer-based Image-Pro Morpho-
metric System by two independent observers in a double-
blind manner.
Statistical analysis
Each polymorphism was tested in controls to ensure the
fitting with Hardy-Weinberg equilibrium. To test the
hypothesis of association between genetic polymor-
phisms and CRC, multivariate methods based on logistic
regression analyses were used. Allele and genotype fre-
quencies in all subjects were calculated by direct counting.
Hardy-Weinberg equilibrium was tested using the Fisher's
exact test. The strength of the gene-cancer associations was
measured by odds ratio (OR) and its 95% confidence
interval (CI). P < 0.05 was considered statistically signifi-
cant. The SPSS was used in the statistical analysis.
Results
Polymorphism of ICAM-1 K469 E may be associated with 
CRC risk
The polymorphisms of ICAM-1 in all cases and controls
are shown in Table 1, which were conformed to Hardy-
Weinberg equilibrium (P > 0.05). In either CRC cases or
controls, only GG genotype of ICAM-1 exon 4 (G241R)
was identified, while the exon 6 (K469E) homozygousJournal of Experimental & Clinical Cancer Research 2009, 28:139 http://www.jeccr.com/content/28/1/139
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and heterozygous individuals were observed (Figure 1).
The distribution of the ICAM-1 K469E genotypes was sig-
nificantly different between CRC cases and controls (P <
0.05). In 102 controls, the K allele frequency was 63.73%,
which is different from that in the cancer cases (73.56%).
Subjects with K allele in CRC had a 1.58-fold increase,
compared with controls (P = 0.041). K allele was signifi-
cantly associated with a increased risk of CRC (OR = 1.58,
χ2 = 4.194, 95% CI, 1.02~2.46, P = 0.041). The frequency
of KK genotype in CRC cases was more than that in the
controls (57.47% vs 42.16%, χ2 = 4.406, P = 0.036). Sub-
jects with KK genotype had a 1.85-fold increase in CRC
risk compared with those with KE+EE genotypes.
Polymorphism of ICAM-1 K469E is associated with tumor 
differentiation
The potential associations of the ICAM-1 K469E genotype
with tumor characteristics are presented in Table 2. No
correlation was found between K469E genotypes and
tumor location, presence of lymph node metastases,
Dukes stage, or age and gender at diagnosis. The KK geno-
type was more frequently found in cases with a well-differ-
entiated CRC (P  = 0.033) (Figure 2A and Table 2),
although with the increased CRC risk. In contrast, the
tumor tissues from the cases with KE+EE genotype
showed poor differentiation compared with those with
KK genotype (P < 0.05). The results suggest that there is
correlation between the K469E genotype and the pheno-
typical characteristics of CRC.
KK genotype is correlated with increase in ICAM-1 
expression in tumor tissues
We next set out to assess whether the K469E genotype is
correlated with differences in ICAM-1 expression using
lysate extracted from the tumor and matched adjacent
normal tissues of CRC patients with KK or KE+EE geno-
types. There were no differences in ICAM-1 level in
matched normal tissues of all tested patients. KK genotype
patients showed an increase in the expression of ICAM-1
protein in tumor tissues relative to the matched normal
tissues (P < 0.05, Figure 2B and 2C). However, the differ-
ence of ICAM-1 level between tumor and matched normal
tissues was not observed in the patients with KE+EE geno-
types. Meanwhile, ICAM-1 level was higher in the tumor
tissues of individuals with KK genotype than that of the
KE+EE genotypes (P < 0.05). We also observed that the
distribution of ICAM-1 was exclusively extracellular in all
colorectal tumors (Figure 2D and 2E). Taken together,
Table 1: Allele and genotype frequencies of the ICAM-1 K469E polymorphisms in CRC cases and controls
CRC (n = 87) (%) Controls (n = 102) (%) P OR (95% CI)
Genotype
KK 50 (57.47) 43 (42.16)
KE 28 (32.18) 44 (43.14) 0.036a 1.85 (1.04~3.31)b
EE 9 (10.35) 15 (14.7)
Allele
K
E
128 (73.56)
46 (26.44)
130 (63.73)
74 (36.27)
0.041 1.58 (1.02~2.46)c
OR, odds ratio; CI, confidence interval.
a, Genotypes: KK vs KE+EE.
b, OR for KK vs KE+EE genotypes in CRC.
c, OR for K vs E allele in CRC.
ICAM-1 G241R and K469E genotypes Figure 1
ICAM-1 G241R and K469E genotypes. Lane M: Marker; 
Primers: G241-E469 (lane 1,5,9); G241-K469(lane 2,6,10); 
R241-E469(lane 3,7,11); R241-K469 (lane 4,8,12).
Table 2: Distribution of various genotypes of ICAM-1 K469E in 
relation to clinicopathological and other variables in CRC cases
Variables Cases (n) KK KE+EE χ2 P
Age
≤ 55 27 16 11 0.051 0.821
> 55 60 34 26
Gender
Male 49 28 21 0.005 0.944
Female 38 22 16
Tumor location
Colon 30 14 16 0.004 0.95
Rectum 57 27 30
Differentiation
Well and moderately 62 33 29 4.564 0.033
Poorly 25 7 18
Metastasis
No 75 41 34 1.75 0.186
Yes 12 9 3
Dukes stages
A+B 50 30 20 0.308 0.579
C+D 37 20 17Journal of Experimental & Clinical Cancer Research 2009, 28:139 http://www.jeccr.com/content/28/1/139
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Polymorphism of ICAM-1 K469E is associated with cancer differentiation and ICAM-1 expression in CRC Figure 2
Polymorphism of ICAM-1 K469E is associated with cancer differentiation and ICAM-1 expression in CRC. (A), 
Representative histological sections of CRC with KK and EE genotypes (Magnification, × 400); (B), Western blot analysis for 
ICAM-1 expression of CRC with KK, KE and EE genotypes; (C), Densitometric scanning of Western blots, n = 15, * P < 0.05 vs 
controls; # P < 0.05 vs CRC with KK genotype; (D), Representative ICAM-1 staining of the cross sections of CRC with KK, KE 
and EE genotypes (Magnification, × 400); (E), Average IOD of ICAM-1 staining of CRC cross sections (n = 15). IOD represents 
relative ICAM-1 protein level in tumor tissues. * P < 0.05 vs KE+EE genotypes.Journal of Experimental & Clinical Cancer Research 2009, 28:139 http://www.jeccr.com/content/28/1/139
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these results indicate that ICAM-1 protein is accumulated
in CRC tissues with KK genotype.
Discussion
Polymorphisms of ICAM-1 K469E and G241R are com-
mon genetic variation in populations and associated with
several autoimmune diseases, such as multiple sclerosis,
type 1 diabetes, or Crohn's disease [12,16,17]. In current
study, we have found only GG genotype individuals in
either CRC cases or normal controls. The variants in
G241R were not observed in our tested population, sug-
gesting that the polymorphisms of G241R may be rare in
Chinese, consistent with the Japanese and Koreans,
respectively, probably reflecting that there is a common
ancestor in these populations [16]. Our observation is dif-
ferent from the previous study concerning the G allele fre-
quency in European-American population that showed
less G allele frequency (0.796-0.971) [12,18,19]. The dis-
tribution of K469E genotypes and allele frequencies in
exon 6 of the ICAM-1 was significantly different between
CRC patients and controls, and between patients with
well differentiation and poor differentiation of tumor tis-
sues. In CRC patients, the KK genotype was found more
frequently than in the controls. The previous studies have
shown that the K allele frequency is 0.437-0.630 in differ-
ent populations [16,20]. The KK genotype frequency in
patients with well-differentiated tumor tissues was more
than that in those of poor differentiation. Although the
significance and the functional or therapeutic relevance of
our findings remain to be elucidated, the most important
finding is that the poor prognosis of CRC seems to be
associated with allele E.
Although it is unclear how the ICAM-1 K469E polymor-
phism contributes to the pathogenesis of CRC, we found
that the increase in ICAM-1 expression was accompanied
by well-differentiation in tumor tissues of KK genotype
patients. ICAM-1, as a surface glycoprotein, is expressed
on vascular endothelium, macrophages, and activated
lymphocytes, and mediates leukocyte circulation and
extravasation from the blood into the areas of inflamma-
tion and macrophage differentiation [21-23]. The epithe-
lial cells of adult colon do not normally express ICAM-1
which can be expressed subsequent to malignant transfor-
mation [24,25]. ICAM-1 expression decreases CRC metas-
tasis and suppress cancer progression via promoting
tumor cell motility and attachment to the extracellular
matrix [6]. The previous study has showed that expression
level of ICAM-1 is high in well differentiated tumor cells
and low levels in poorly differentiated cells, and demon-
strated a mechanism whereby ICAM-1 expression pro-
motes CRC differentiation and retard metastasis [7].
ICAM-1 plays a role in promoting lymphocyte-mediated
tumor killing [26], and this occurs as a result of enhanced
binding of peripheral blood mononuclear cells to the
tumor cells and subsequent tumor cell lysis [27]. Yet the
study suggests that ICAM-1 enhances tumor cell attach-
ment to the extracellular matrix by promoting motility in
the context of remodeling, and appears to be acting as a
morphogen [7]. These findings provide a possible reason
why increasing of ICAM-1 expression occurs in well differ-
entiated CRC tissues.
Conclusion
Our study herein provides a potential genetic factor for
the differentiation of CRC that correlates with ICAM-1
K469E polymorphisms because of different ICAM-1
expression. However, we are unable to define the associa-
tion of the ICAM-1 K469E polymorphisms with CRC risk
owing to the limitations of the size of the CRC and control
populations in the present study. Our findings may help
to evaluate the prognosis of CRC according to the individ-
ual genetic background.
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